

ABSTRACT

SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB

The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

FIGURE 1